Shandong Sanyuan Biotechnology Co., Ltd. (hereinafter referred to as "the Company") has opened special accounts for fundraising in accordance with relevant laws, regulations, and normative documents for its initial public offering on the Shenzhen Stock Exchange's Growth Enterprise Market. Recently, the cancellation procedures for the fundraising special accounts have been completed, and the specific situation is announced as follows:
1. Basic Situation of Fundraising
With the approval of the China Securities Regulatory Commission regarding the initial public offering of shares (Approval No. [2021] 4073), and with the consent of the Shenzhen Stock Exchange, the Company publicly issued 33,721,000 ordinary shares (A shares) at a par value of RMB 1.00 per share, with an issue price of RMB 109.3 per share, raising a total of RMB 368,570.53 million. After deducting underwriting fees and other issuance expenses, the net amount raised was RMB 354,664.46 million, which has been verified by the accounting firm with verification report No. [2022] 0289.